Vir Biotechnology, Inc. (VIR) Stock Grade

About Vir Biotechnology, Inc.'s fundamentals

Vir Biotechnology is a $1.8 billion biotechnology company currently operating at a significant loss, with a net margin of -638.9% based on its latest annual results. The company's revenue declined 7.6% year-over-year, indicating a contraction in its top-line performance. Given the net loss and negative profitability metrics, traditional valuation ratios like P/E ratio and return on equity are not meaningful, and the company does not pay a dividend. As an early-stage biotech firm, Vir's financial profile reflects the typical characteristics of a development-stage company investing heavily in research and drug development.